Form 4: AbbVie Director Alpern Acquires Stock Equivalent Units

AbbVie Director Robert J. Alpern reported the acquisition of 34 stock equivalent units on December 31, 2025, as part of director compensation.

Summary

• Robert J. Alpern, a Director at AbbVie Inc., acquired 34 stock equivalent units.
• The transaction occurred on December 31, 2025.
• These units were credited as director fees to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie.
• The units are valued at $228.49 each.
• The stock equivalent units in the AbbVie account will be paid in cash, generally at age 65 or upon retirement from AbbVie's board.
• The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
• Following this transaction, Alpern beneficially owns a total of 10,257 stock equivalent units.
• The reported balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The acquisition of stock equivalent units by a director is a neutral to slightly positive event, indicating continued alignment of interests with shareholders through a standard compensation mechanism.

Positives

• Director Alpern's beneficial ownership of AbbVie stock equivalent units increased, further aligning his financial interests with those of shareholders.
• The acquisition is part of a structured, long-term compensation plan, indicating ongoing commitment from the director.

Negatives

• No specific negative aspects are identified in this routine disclosure of director compensation.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing indicates that the acquired stock equivalent units will be paid in cash generally at age 65 or upon retirement from AbbVie's board, suggesting a long-term compensation structure tied to the company's performance and the director's tenure.

Industry Context

This transaction represents a routine compensation event for a director in the pharmaceutical industry, where equity-linked compensation is common to align executive and director interests with long-term shareholder value. It does not reflect broader industry trends or competitive shifts.

Comparison to Industry Standards

• The use of stock equivalent units as part of director compensation is a common practice across the pharmaceutical and broader corporate landscape, aligning director incentives with company performance.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize similar equity-based compensation structures for their non-employee directors, often involving restricted stock units or deferred stock units that vest over time or upon retirement, providing a long-term incentive for board oversight and strategic guidance.

Related Party Transactions

• Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie, which are standard related party transactions for director compensation.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of shareholders, as the value of the stock equivalent units is tied to AbbVie's stock performance.
• Employees/Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this routine director compensation disclosure.

Next Steps

• No specific future actions or milestones are mentioned beyond the eventual cash payment of the stock equivalent units upon the director reaching age 65 or retiring from the board.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of stock equivalent units by a director as part of their compensation. While it indicates continued alignment of interests, it does not present new information significant enough to alter an investment thesis or warrant a 'buy' or 'sell' recommendation. The transaction is expected and reflects standard corporate governance practices.

Keywords

AbbVie, ABBV, Form 4, Insider Transaction, Director Compensation, Stock Equivalent Units, Beneficial Ownership, Robert J. Alpern